The First National Plan to Address Alzheimer's Disease was released in May of 2012 and set a blueprint for research in Alzheimer's disease (AD) to achieve the goal of effective treatment and prevention of the disease by 2025. Toward that goal, the Mayo Alzheimer's Disease Research Center (ADRC) is pursuing research to accomplish that goal. The Center will be comprised of five cores: Administrative Core to oversee the operations of the Center; Clinical Core to recruit and characterize subjects along the AD spectrum and for the AD-related dementias; Data Management and Statistical Core to collect, refine and analyze data and be compliant with the requirements of the National Alzheimer's Coordinating Center; Neuropathology Core to perform detailed neuropathological studies on autopsy specimens and disseminate genetic and other biospecimens to collaborators; Outreach, Recruitment and Education Core to assist in the recruitment and characterization of subjects for research purposes. The ADRC is also proposing three new research projects including one by a junior investigator. Project 1, Improving Clinical Prediction of Dementia Pathology and Long-Term Outcomes Using Imaging, by Prashanthi Vemuri, Ph.D., will develop a software methodology using clinical and imaging data to predict dementia subtypes; Project 2, Validating HDAC6 as a Novel Therapeutic Target for Alzheimer's Tauopathy, principal investigator Leonard Petrucelli, Ph.D., will validate inhibition of cytosolic histone deacetylase 6 that modulates the accumulation of hyperphosphorylated tau as a possible strategy for the treatment of AD; Project 3, ApoE Isoforms in Brain Vasculature and CAA, Goujun Bu, Ph.D., will investigate the roles of ApoE and ApoE receptors in the pathogenesis of AD. The ADRC will continue to maintain an active cohort of research subjects and will recruit a new cohort of at-risk subjects for Lewy body disorders. The Center will continue to serve as the nidus for AD research at the Mayo Clinic and will interact with the National Institute on Aging and other Alzheimer's Disease Centers around the country. The Center will remain flexible and adapt to new directions as the field of AD and related dementia research progresses.

Public Health Relevance

Alzheimer's disease (AD) may be the defining healthcare condition of our generation. The First Plan to Address Alzheimer's Disease for the United States was released in May of 2012 and outlined a blueprint for research and care on individuals with AD and AD-related dementias. The Mayo Alzheimer's Disease Research Center will pursue themes related to the National Plan in an attempt to have an impact on this disease within ten years.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG016574-20
Application #
9475169
Study Section
Special Emphasis Panel (ZAG1)
Program Officer
Silverberg, Nina B
Project Start
1999-05-01
Project End
2019-04-30
Budget Start
2018-05-15
Budget End
2019-04-30
Support Year
20
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Baker, Darren J; Petersen, Ronald C (2018) Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives. J Clin Invest 128:1208-1216
Ramsey, Christine M; Gnjidic, Danijela; Agogo, George O et al. (2018) Longitudinal patterns of potentially inappropriate medication use following incident dementia diagnosis. Alzheimers Dement (N Y) 4:1-10
Tse, Kai-Hei; Cheng, Aifang; Ma, Fulin et al. (2018) DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer's disease and dementia. Alzheimers Dement 14:664-679
Ramanan, Vijay K; Przybelski, Scott A; Graff-Radford, Jonathan et al. (2018) Statins and Brain Health: Alzheimer's Disease and Cerebrovascular Disease Biomarkers in Older Adults. J Alzheimers Dis 65:1345-1352
Knopman, David S; Lundt, Emily S; Therneau, Terry M et al. (2018) Joint associations of ?-amyloidosis and cortical thickness with cognition. Neurobiol Aging 65:121-131
Hadjichrysanthou, Christoforos; McRae-McKee, Kevin; Evans, Stephanie et al. (2018) Potential Factors Associated with Cognitive Improvement of Individuals Diagnosed with Mild Cognitive Impairment or Dementia in Longitudinal Studies. J Alzheimers Dis 66:587-600
Ferman, Tanis J; Aoki, Naoya; Crook, Julia E et al. (2018) The limbic and neocortical contribution of ?-synuclein, tau, and amyloid ? to disease duration in dementia with Lewy bodies. Alzheimers Dement 14:330-339
Hanfelt, John J; Peng, Limin; Goldstein, Felicia C et al. (2018) Latent classes of mild cognitive impairment are associated with clinical outcomes and neuropathology: Analysis of data from the National Alzheimer's Coordinating Center. Neurobiol Dis 117:62-71
Schaffert, Jeff; LoBue, Christian; White, Charles L et al. (2018) Traumatic brain injury history is associated with an earlier age of dementia onset in autopsy-confirmed Alzheimer's disease. Neuropsychology 32:410-416
Besser, Lilah; Kukull, Walter; Knopman, David S et al. (2018) Version 3 of the National Alzheimer's Coordinating Center's Uniform Data Set. Alzheimer Dis Assoc Disord 32:351-358

Showing the most recent 10 out of 1014 publications